Navigation Links
MEDPOR Enophthalmos Shapes

ProductsMEDPOR Enophthalmos Shapes
Company Porex Surgical Products Group
Item MEDPOR Enophthalmos Shapes
Features Enophthalmos wedges are provided in both right and left orientation and in two sizes: regular, with 2ml of volume, and large, with 3 ml of volume
Description Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size.
Info Porex Surgical Products Group
Customer Service: (800) 521-7321
Web site: http://www.porexsurgical.com

Related medicine products :

1. MEDPOR Orbital Rim Implant (IMORI)
2. MEDPOR Orbital Rim Onlay Implants
3. MEDPOR Orbital Rims
4. MEDPOR Inferior Orbital Rims
5. MEDPOR Midface Rim
6. MEDPOR Superior Lateral Orbital Rim
7. MEDPOR Complete Orbit Complex
8. MEDPOR 2/3 Orbit Complex
9. MEDPOR Miniplate Channel Implant
10. MEDPOR Barrier Miniplate Channel Implant
11. MEDPOR Sphere Inserter
...ly invasive surgery is founded on superior medical...-Chip cameras, 1-Chip cameras, Light sources, Coup...nding needs., ,Superior resolution and color repr...meras, and are the benchmark by which all other me...
...ra System provides easy-to-use features, auto iris...amera head construction is based on Solos durable ...era System, International (GS9900-PAL) includes: ,...rd and video cables , (GS 9905) Camera head with 3...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery.
Medicine Products:
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...the University of Washington and other members of ...erstanding of how the human genome functions . Whi...ed mainly on genes, this study provides insight in... vast majority of the genome. Buried in non-gene...
...ernment has sanctioned funds for districts affecte...urtail the deadly virus . Chief Minister V S Ach...granted to the affected districts of Kottayam and ...t the disease. He also disclosed that other distr...
World Blood Donor Day
...s found that a breakdown of myelin is associated w...Last month, Dr. George Bartzokis, director of the ...ic, suggested in the journal Alzheimer's and Dem...develops late in life promotes the enlargement of ...
Other Medicine News:Health News:Researchers Cracking the Human Genome Function 2Health News:Researchers Cracking the Human Genome Function 3Health News:World Blood Donor Day 2Health News:Myelin Associated With Early Evolution of Huntington's Disease 2Health News:Myelin Associated With Early Evolution of Huntington's Disease 3
(Date:10/13/2008)...e/ -- Neuronascent, Inc.,( http://www.neuronascent...ed,funding from multiple sources to further the de...ting Alzheimer,s disease, depression and,ischemia.... Maryland,Department of Business and Economic Deve...ustrial Partnerships in collaboration with Univers...
(Date:10/13/2008)...Higher Sensitivity and Specificity, than Other Ra...referred test in all phases of thi...wswire/ -- AT First Diagnostic LLC an,emerging wor...its, today,announced that a recent evaluation cond...h of the FirstVue(TM) HBSAG Test, was released at ...
(Date:10/13/2008)...e Cancer Populations Facilitates ... 13 /- Rubicon Genomics, Inc. today,a...fy DNA samples for The,Cancer Atlas Genome Project...tandardize total genomic,DNA from 3,000 tissue and...enomePlex(TM) Whole Genome Amplification technolog...
(Date:10/12/2008)...ombination with Chemotherapy, FREMONT, Calif. Oct...a,development-stage pharmaceutical company discove...based therapeutics, today announced that the,journ...f siRNA targeting,its proprietary target gene agai...ion dated October 1, 2008. The paper, entitled "RN...
Breaking Medicine Technology:Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 1841 1PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 1841 2Riley Hospital for Children 26amp 3B Capital Institute of Pediatrics become international sister hospitals 17105 1Riley Hospital for Children 26amp 3B Capital Institute of Pediatrics become international sister hospitals 17105 2Researchers evaluating food allergy treatment 17102 1Researchers evaluating food allergy treatment 17102 2Inaugural Kirkham Gold Medal presented to expert on soil physics 2942 1Inaugural Kirkham Gold Medal presented to expert on soil physics 2942 2
... 2007 /PRNewswire/ --,Pieris AG, a bio-pharmaceuti...s of targeted human protein therapeutics, today an...effective products for,the potential treatment of ...calin(R) candidate, the Company reports that the,p...of action via,the lungs. , PRS-060 has been select...
... -- Portola,Pharmaceuticals, Inc. announced positi...an oral Factor Xa inhibitor, today at the XXI,Cong...d Haemostasis,(ISTH) in Geneva, Switzerland. The E...ive, and well tolerated for the,prevention of veno...ing total knee replacement (TKR) surgery. Portola ...
Other Medicine Technology:Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4